We are focused on bringing to market medical products that meet the needs of specialist physicians and their patients, thereby building a leading specialist healthcare business that delivers superior returns to shareholders.
Our strategy is to expand our portfolio of marketed specialty pharmaceutical and interventional oncology products through acquisition, development and commercial activities.
We established US commercial operations in late 2010 and now sell our specialty pharmaceutical and interventional oncology products direct to physicians. We are now scaling up those operations. In 2012 we received approval and launched Voraxaze® (glucarpidase) in the US. We have also acquired US and EU commercial rights to uridine triacetate, an experimental treatment for accidental overexposure to the chemotherapeutic 5-FU which is in its final stages of development by Wellstat Therapeutics Corporation.
Outside of the US our strategy is to work with partners and distributors to register and sell our products. We will keep this under review and will consider direct sales in certain territories where the economics make sense and where we have the right capabilities. We are actively pursuing an international expansion strategy for our interventional oncology products, in particular in Asia where high infection rates of hepatitis B and C have led to a high incidence of liver cancer.
Our research and development focus is on products that we can commercialise ourselves. We are developing Varisolve® (polidocanol endovenous microfoam (PEM)), for the treatment of varicose veins and the development candidate is in regulatory review with the US Food and Drug Administration (FDA). We plan to market PEM ourselves in the US reimbursed sector. We are also conducting a number of exploratory studies on our interventional bead products and plan to initiate regulatory studies designed to expand the indicated uses for these products.